Watch and wait with dostarlimab for localized stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a drug called dostarlimab for people with a specific type of stomach cancer that has not spread. The goal is to see if the drug can make the tumor disappear, so you might not need surgery right away.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and feel well enough to be up and about (ECOG score 0 or 1).
- You have stomach or gastroesophageal junction cancer that has not spread to other parts of the body (stage cT2-T4, Nx, M0).
- Your tumor has a specific genetic feature called dMMR/MSI-H, which must be confirmed by the study team.
- You haven't had chemotherapy, radiation, or immunotherapy for this cancer before.
- You are willing to have an endoscopy with biopsies and provide tissue samples.
- You are able to participate in study visits and follow the treatment plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.
This study tests a combination of three treatments—JS107, toripalimab (an immunotherapy), and chemotherapy—for advanced stomach cancer that has a specific protein marker called CLDN18.2. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new approach: giving the immunotherapy drug dostarlimab along with a short course of radiation before surgery, with the goal of avoiding surgery in many patients. It is for people with a specific type of rectal cancer (MSI-H or dMMR) that has not spread to other organs.
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
This trial studies dostarlimab given around the time of colon cancer surgery for people with untreated, resectable (operable) stage T4N0 or stage III colon cancer that has specific tumor markers. It may help shrink or eliminate the cancer before or after surgery by boosting the immune response.
This trial tests an investigational immunotherapy drug called dostarlimab given before surgery for colon cancer. It is for people whose tumor is MMR-proficient (also called MSS) and is large enough or has spread to nearby lymph nodes but not to other parts of the body. The goal is to see if this treatment can shrink the tumor before surgery.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.